Limits...
Age distribution of patients with advanced non-melanoma skin cancer in the United States.

Dacosta Byfield S, Chen D, Yim YM, Reyes C - Arch. Dermatol. Res. (2013)

Bottom Line: MET patients had at least two claims with a metastasis code at least 30 days apart.Although NMSCs rarely progress, the number of patients with advanced disease is significant.Further studies to determine proportions of advanced NMSC by subtype are needed.

View Article: PubMed Central - PubMed

Affiliation: OptumInsight, 12125 Technology Drive MN002-0258, Eden Prairie, MN, 55344, USA, stacey.dacostabyfield@optum.com.

ABSTRACT
The epidemiology of non-melanoma skin cancer (NMSC) is not well understood due to exclusion from most US cancer registries. Patients with at least two claims with a NMSC diagnosis (ICD-9-CM 173.xx) at least 60 days apart, or at least one claim for a NMSC-specific treatment from 1/2010 to 12/2010, were identified from a large US commercial insurance claims database and grouped into one of three cohorts: metastatic (MET), locally advanced (LA), or "all other". MET patients had at least two claims with a metastasis code at least 30 days apart. LA patients had at least two visits to a medical oncologist, one diagnostic imaging service, two radiation therapy services, or one visit to two or more physician specialties. Remaining patients were "all other". Incidence and prevalence of NMSC were calculated from among the total number of persons continuously enrolled in the plan during the study period and standardized to the 2010 US population. From among 6,610,256 patients, there were 47,451 incident cases of NMSC (MET n=16, LA n=387, all other n=47,048). The age-adjusted incidence rate of 693 per 100,000 persons (2010 population) approximates to 2,139,535 total NMSC cases in the US (0.7% of population). 671 prevalent cases had advanced disease (MET n=43, LA n=628); an age-adjusted rate of 0.6 and 10 per 100,000 US persons equivalent to 1,993 and 29,841 MET and LA cases, respectively. Although NMSCs rarely progress, the number of patients with advanced disease is significant. Further studies to determine proportions of advanced NMSC by subtype are needed.

Show MeSH

Related in: MedlinePlus

Sample selection and attrition
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3824573&req=5

Fig1: Sample selection and attrition

Mentions: From among the 6,610,256 health plan enrollees with continuous enrollment from 1 January 2009 to 31 December 2010, a total of 68,782 patients had evidence of NMSC during 2010 (Fig. 1). After excluding 7,731 patients with evidence of other primary cancer, there were a total of 61,051 patients with evidence of NMSC during 2010. Among these, 671 patients had evidence of advanced disease (MET n = 43 and LA n = 628) during 2010 and were considered the prevalent population. In addition, a total of 47,451 patients had no evidence of NMSC during 2009 and were considered incident cases (MET n = 16, LA n = 387, all other n = 47,048).Fig. 1


Age distribution of patients with advanced non-melanoma skin cancer in the United States.

Dacosta Byfield S, Chen D, Yim YM, Reyes C - Arch. Dermatol. Res. (2013)

Sample selection and attrition
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3824573&req=5

Fig1: Sample selection and attrition
Mentions: From among the 6,610,256 health plan enrollees with continuous enrollment from 1 January 2009 to 31 December 2010, a total of 68,782 patients had evidence of NMSC during 2010 (Fig. 1). After excluding 7,731 patients with evidence of other primary cancer, there were a total of 61,051 patients with evidence of NMSC during 2010. Among these, 671 patients had evidence of advanced disease (MET n = 43 and LA n = 628) during 2010 and were considered the prevalent population. In addition, a total of 47,451 patients had no evidence of NMSC during 2009 and were considered incident cases (MET n = 16, LA n = 387, all other n = 47,048).Fig. 1

Bottom Line: MET patients had at least two claims with a metastasis code at least 30 days apart.Although NMSCs rarely progress, the number of patients with advanced disease is significant.Further studies to determine proportions of advanced NMSC by subtype are needed.

View Article: PubMed Central - PubMed

Affiliation: OptumInsight, 12125 Technology Drive MN002-0258, Eden Prairie, MN, 55344, USA, stacey.dacostabyfield@optum.com.

ABSTRACT
The epidemiology of non-melanoma skin cancer (NMSC) is not well understood due to exclusion from most US cancer registries. Patients with at least two claims with a NMSC diagnosis (ICD-9-CM 173.xx) at least 60 days apart, or at least one claim for a NMSC-specific treatment from 1/2010 to 12/2010, were identified from a large US commercial insurance claims database and grouped into one of three cohorts: metastatic (MET), locally advanced (LA), or "all other". MET patients had at least two claims with a metastasis code at least 30 days apart. LA patients had at least two visits to a medical oncologist, one diagnostic imaging service, two radiation therapy services, or one visit to two or more physician specialties. Remaining patients were "all other". Incidence and prevalence of NMSC were calculated from among the total number of persons continuously enrolled in the plan during the study period and standardized to the 2010 US population. From among 6,610,256 patients, there were 47,451 incident cases of NMSC (MET n=16, LA n=387, all other n=47,048). The age-adjusted incidence rate of 693 per 100,000 persons (2010 population) approximates to 2,139,535 total NMSC cases in the US (0.7% of population). 671 prevalent cases had advanced disease (MET n=43, LA n=628); an age-adjusted rate of 0.6 and 10 per 100,000 US persons equivalent to 1,993 and 29,841 MET and LA cases, respectively. Although NMSCs rarely progress, the number of patients with advanced disease is significant. Further studies to determine proportions of advanced NMSC by subtype are needed.

Show MeSH
Related in: MedlinePlus